2023-2024 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers
The fully captioned video and edited transcript will be posted within the next few days.
Click here to view the recording with the integrated audio transcript using the password below.
Password: 9r+6G%U8
“Please note special time of this COCA Call.”
This COCA Call will be held on Friday, March 27, 2020
This COCA Call will be held on Friday, March 27, 2020
= Overview
Influenza remains a serious threat to children due to its potential to cause severe morbidity and mortality. Annual influenza vaccination is the most effective way to prevent influenza illness and associated complications, including death. Clinicians play a critical role in the immunization of children and their family members and caregivers.
During this COCA Call, presenters will provide an overview of influenza prevention and treatment recommendations for the 2023–2024 season from the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC).
Presenters
Fatimah Dawood, MD, FAAP
Pediatrician and Medical Officer
Influenza Prevention and Control Team
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Kristina A. Bryant, MD, FAAP, FPIDS
Member, Committee on Infectious Diseases, American Academy of Pediatrics
Professor of Pediatrics, University of Louisville School of Medicine
Hospital Epidemiologist at Norton Children’s Hospital
Director for System Pediatric Epidemiology and Infectious Diseases, Norton Children’s Medical Group, Louisville, KY
When:
Thursday, August 31, 2023,
2:00 PM – 3:00 PM ET
Webinar Link:
https://www.zoomgov.com/j/1600020619
Webinar ID: 160 002 0619
Passcode: 752590
Telephone:+1
+1 646 828 7666 US (New York)
One-tap mobile:
+16692545252,,1600020619#,,,,*752590# US (San Jose)
+16469641167,,1600020619#,,,,*752590# US (US Spanish Line
When:
Tuesday, July 26, 2022,
2:00 PM – 3:00 PM ET
Webinar Link:
https://www.zoomgov.com/j/1615119188
Passcode: 143543
Dial In:
US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
One-tap mobile:
US: +16692545252,,1615119188#,,,,*143543# or +16468287666,,1615119188#,,,,*143543#
Webinar ID: 161 511 9188
Add to Calendar
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
To receive continuing education (CE) for WD4520-083123 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – 2023-2024 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers, please visit CDC TRAIN and search for the course in the Course Catalog using WD4520-083123. Follow the steps below by October 3, 2025.
- Register for and complete the course.
- Pass the post-assessment at 75%.
- Complete the evaluation.
- Visit Your Learning to access your certificates and transcript.
In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation.
CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.
CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-23-081-L04-P and enduring JA4008229-0000-23-082-H04-P.
Once credit is claimed, an unofficial statement of credit is immediately available on CDC TRAIN. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients with the exception of Dr. Kristina Bryant who would like to disclose that she is an investigator on multicenter vaccine trials with Pfizer and Enanta, and receives royalties from Oxford University Press. All of the relevant financial relationships listed for this individual have been mitigated.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use except Dr. Fatimah Dawood who would like to disclose that she will discuss neuraminidase inhibitor medications (antivirals) that are FDA approved only for treating uncomplicated influenza.
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.
Fees: No fees are charged for CDC’s CE activities.
Sign up to receive COCA Call Announcements, COCA Newsletters and other COCA resources by entering your email address: